The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia
Abstract
On November 13, 2013, the FDA granted accelerated approval to ibrutinib (IMBRUVICA capsules; Pharmacyclics, Inc.) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. On February 12, 2014, the FDA granted accelerated approval for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. Ibrutinib is a first-in-class Bruton's tyrosine kinase (BTK) inhibitor that received all four expedited programs of the FDA: Fast-Track designation, Breakthrough Therapy designation, Priority Review, and Accelerated Approval. Both approvals were based on overall response rate (ORR) and duration of response (DOR) in single-arm clinical trials in patients with prior treatment. In MCL (N = 111), the complete and partial response rates were 17.1% and 48.6%, respectively, for an ORR of 65.8% [95% confidence interval (CI), 56.2%–74.5%]. The median DOR was 17.5 months (95% CI, 15.8–not reached). In CLL (N = 48), the ORR was 58.3% (95% CI, 43.2%–72.4%), and the DOR ranged from 5.6 to 24.2 months. The most common adverse reactions (≥30% in either trial) were thrombocytopenia, diarrhea, neutropenia, bruising, upper respiratory tract infection, anemia, fatigue, musculoskeletal pain, peripheral edema, and nausea. Clin Cancer Res; 21(16); 3586–90. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128 · cited 1×
“Ibrutinib is an inhibitor of BTK, a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways that activate pathways necessary for B-cell trafficking, chemotaxis, and adhesion (8, 9).”
Woyach, J. A., Smucker, K., Smith, L. L., Lozanski, A., Zhong, Y., Ruppert, A. S., Lucas, D., Williams, K., Zhao, W., Rassenti, L., et al. (2014) · Blood · doi:10.1182/blood-2013-09-527853 · Cited by 280
Cited by
Extracellular matrix and its therapeutic potential for cancer treatment
Huang, J., Zhang, L., Wan, D., Zhou, L., Zheng, S., Lin, S., & Qiao, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00544-0 · Cited by 962
Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective
Kumar, A., Singh, A. K., Singh, H., Vijayan, V., Kumar, D., Naik, J., Thareja, S., Yadav, J. P., Pathak, P., Grishina, M., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16020299 · Cited by 363
Dreyling, M., Morschhauser, F., Bouabdallah, K., Bron, D., Cunningham, D., Assouline, S. E., Verhoef, G., Linton, K., Thieblemont, C., Vitolo, U., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx289 · Cited by 265
Walliser, C., Hermkes, E., Schade, A., Wiese, S., Deinzer, J., Zapatka, M., Désiré, L., Mertens, D., Stilgenbauer, S., & Gierschik, P. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.746842 · Cited by 51
Yoon, S.-B., Hong, H., Lim, H.-J., Choi, J. H., Choi, Y. P., Seo, S. W., Lee, H. W., Chae, C. H., Park, W.-K., Kim, H. Y., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.12.001 · Cited by 44
Metadata
- Authors
- de Claro, R. A., McGinn, K. M., Verdun, N., Lee, S.-L., Chiu, H.-J., Saber, H., Brower, M. E., Chang, C. J. G., Pfuma, E., Habtemariam, B., Bullock, J., Wang, Y., Nie, L., Chen, X.-H., Lu, D. (., Al-Hakim, A., Kane, R. C., Kaminskas, E., Justice, R., Farrell, A. T., & Pazdur, R.
- Venue
- Clinical Cancer Research
- Published
- 2015-08-13
- Volume
- 21
- Issue
- 16
- Pages
- 3586-3590
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W1908764360
- Cited by
- 171
- References
- 4
- FWCI
- 7.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-2225
- The paper
- de Claro, R. A., McGinn, K. M., Verdun, N., Lee, S.-L., Chiu, H.-J., Saber, H., Brower, M. E., Chang, C. J. G., Pfuma, E., Habtemariam, B., Bullock, J., Wang, Y., Nie, L., Chen, X.-H., Lu, D. (., Al-Hakim, A., Kane, R. C., Kaminskas, E., Justice, R., . . . Pazdur, R. (2015). FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-2225
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.